| Literature DB >> 29404027 |
Chitra Subramani1, Arivukkodi Rajakkannu1, Arunadevi Rathinam2, Sudesh Gaidhani2, Ilavarasan Raju2, Dhiman Vaidya Kartar Singh3.
Abstract
Premna integrifolia Linn. is a medicinal plant used in "Dhasamula" drug preparation of Ayurvedic systems of medicine in the treatment of various ailments like bronchitis, dyspepsia, liver disorders, piles, constipation, hyperlipidemia and fever. The anti-atherosclerotic activity of hydroalcoholic extract (HAE) of root bark of P. integrifolia was evaluated in high fat diet induced atherosclerosis rats. Sixty Wistar rats were divided into six groups: the first group served as control, the second group was fed with high fat diet and the other three groups were fed with high fat diet along with various concentrations of HAE and the last group was treated with atorvastatin for 30 days. Lipid and lipoprotein profile, atherogenic index, and cardiac markers and histopathological evaluation of aorta were determined in high fat diet induced atherosclerosis rats. HAE of P. integrifolia produced a significant and dose-dependent anti-atherosclerotic activity in terms of reduction in lipids and lipoprotein profile, atherogenic index, HMG-CoA reductase activity, marker enzymes such as lactate dehydrogenase (LDH), creatine phosphokinase (CPK), aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP), alteration in collagen and calcium contents, mild mineralization and focal rupture of intima and media of aorta was noticed in treated groups as compared to the control. The results suggested that anti-atherosclerotic activity of HAE of P. integrifolia Linn. was due to its modulatory activity on metabolic pathway of lipid. The results contribute to the validation of the traditional use of Agnimantha in high fat diet induced atherosclerosis rats.Entities:
Keywords: Atherogenic index; Atherosclerosis; Biomarkers; HMG-CoA reductase; P. integrifolia
Year: 2016 PMID: 29404027 PMCID: PMC5686870 DOI: 10.1016/j.jpha.2016.12.002
Source DB: PubMed Journal: J Pharm Anal ISSN: 2214-0883
Body weight (gm) changes in experimental rats.
| Group | Day 1 | Day 7 | Day 14 | Day 21 | Day 30 |
|---|---|---|---|---|---|
| Group I | 107.20±8.31 | 112.90±9.05 | 127.40±5.46 | 132.90±5.76 | 136.80±8.27 |
| (5.32) | (18.84) | (23.97) | (27.61) | ||
| Group II | 105.00±9.23 | 116.10±8.91 | 129.70±7.59 | 140.00±6.73 | 152.00±6.69 |
| (10.57) | (23.52) | (33.33) | (44.76) | ||
| (11.11) | |||||
| Group III | 104.70±8.89 | 113.30±9.97 | 121.90 ±13.55 | 129.40±17.08 | 138.70±21.57 |
| (8.21) | (16.43) | (23.59) | (29.61) | ||
| (9.59) | |||||
| Group IV | 106.00±8.31 | 115.70±9.89 | 123.90±13.95 | 129.90±16.18 | 136.60±20.96 |
| (9.15) | (16.89) | (22.55) | (28.87) | ||
| (11.27) | |||||
| Group V | 103.90±5.88 | 117.00±6.13 | 124.22±12.66 | 129.67±13.83 | 134.67±18.43 |
| (12.61) | (19.56) | (24.80) | (27.69) | ||
| (12.87) | |||||
| Group VI | 105.50±8.93 | 114.60±10.18 | 122.80±10.10 | 134.06±16.05 | 141.33±19.05 |
| (8.63) | (16.39) | (27.07) | (33.96) | ||
| (7.55) |
Values are expressed as mean±SD of respective group of rats. (n=10).
Percentage change in body weight with respect to day 1.
Percentage change in body weight with respect to group II of 30 days.
Percentage change in body weight with respect to group I of 30 days.
Fig. 1Feed consumption of experimental rats (values are expressed as mean of respective group of rats (n=10)).
Organ weights (g) of experimental rats.
| Group | |||
|---|---|---|---|
| Liver | Heart | Kidney | |
| Group I | 7.319±0.744 | 0.792±0.019 | 2.134±0.118 |
| Group II | 8.098±0.336 | 0.764±0.030 | 2.128±0.089 |
| Group III | 7.711±0.289 | 0.758±0.024 | 2.090±0.056 |
| Group IV | 7.413±0.453 | 0.777±0.042 | 2.135±0.117 |
| Group V | 7.178±0.499 | 0.790±0.077 | 2.249±0.145 |
| Group VI | 7.304±0.567 | 0.771±0.044 | 2.144±0.088 |
Values are expressed as mean±SD of 10 rats; ANOVA was used for multiple comparisons.
Estimation of TC, TG and FEA in serum.
| Group | Total cholesterol (mg/L) | Triglycerides (mg/L) | Free fatty acids (mg/L) |
|---|---|---|---|
| Group I | 8.23±1.52 | 6.48±1.64 | 6.48±1.64 |
| Group II | 12.69±1.16## | 11.41±1.90## | 11.41±1.90## |
| Group III | 8.87±1.41** | 8.2±1.77** | 8.22±1.75** |
| Group IV | 8.22±2.83** | 7.99±1.60** | 7.99±1.61** |
| Group V | 8.19±2.18** | 7.14±1.28** | 7.14±1.29** |
| Group VI | 9.68±2.71* | 7.16±1.79** | 7.16±1.79** |
Values are expresses as mean±SD of 10 rats; ANOVA was used for multiple comparison; compared with group I, ##p<0.01; compared with group II, *p<0.05, **p<0.01.
Determination of LDLc, VLDLc and HDLc in serum.
| Group | LDLc (mg/L) | VLDLc (mg/L) | HDLc (mg/L) |
|---|---|---|---|
| Group I | 3.22±0.89 | 1.29±0.33 | 5.55±1.12 |
| Group II | 4.82±0.51## | 2.28±0.38## | 3.75±0.54## |
| Group III | 3.91±0.75 | 1.64±0.36** | 4.69±0.99 |
| Group IV | 3.65±0.88* | 1.59±0.32** | 5.33±1.22* |
| Group V | 3.49±0.56** | 1.43±0.26** | 5.46±0.75* |
| Group VI | 3.63±0.54* | 1.43±0.36** | 5.04±1.28 |
Values are expresses as mean±SD of 10 rats; ANOVA was used for multiple comparison; compared with group I, ##p<0.01; compared with group II, *p<0.05, **p<0.01.
Determination of atherogenic index, TC/HDLc and LDLc/HDLc in serum.
| Group | Atherogenic index | TC/HDLc | LDLc/HDLc |
|---|---|---|---|
| Group I | 0.55±0.49 | 1.55±0.49 | 0.612±0.265 |
| Group II | 2.46±0.65## | 3.11±1.25## | 1.184±0.492## |
| Group III | 0.96±0.50** | 1.96±0.50* | 0.869±0.239 |
| Group IV | 0.54±0.39** | 1.54±0.39** | 0.719±0.220** |
| Group V | 0.52±0.46** | 1.37±0.64** | 0.591±0.269** |
| Group VI | 0.96±0.54** | 1.77±0.80** | 0.684±0.328** |
Values are expresses as mean±SD of 10 rats; ANOVA was used for multiple comparison; compared with group I, ##p<0.01; compared with group II, *p<0.05, **p<0.01.
Activities of ALT, AST and ALP in serum.
| Group | ALT (U/L) | AST (U/L) | ALP (U/L) |
|---|---|---|---|
| Group I | 101.07±23.00 | 118.50±31.15 | 470.10±73.80 |
| Group II | 143.34±10.60## | 162.44±9.14## | 619.11±55.70## |
| Group III | 120.11±25.90 | 132.28±21.80 | 514.60±62.60 |
| Group IV | 109.18±20.40** | 130.89±23.05 | 504.22±90.40* |
| Group V | 107.18±16.80** | 127.32±22.71* | 495.22±64.00* |
| Group VI | 110.74±19.70* | 134.37±27.09 | 531.33±120.20 |
Values are expresses as mean±SD of 10 rats; ANOVA was used for multiple comparison; compared with group I, ##p<0.01; compared with group II, *p<0.05, **p<0.01.
Activities of LDH and CPK in serum.
| Group | LDH (IU/L) | CPK (IU/L) |
|---|---|---|
| Group I | 249.90±42.46 | 166.50±44.40 |
| Group II | 539.78±89.82## | 282.43±35.50## |
| Group III | 432.70±78.02## | 231.28±58.70 |
| Group IV | 374.20±63.54## | 188.48±85.70** |
| Group V | 273.56±58.79** | 165.49±35.50** |
| Group VI | 309.22±61.24** | 195.09±57.00* |
Values are expresses as mean±SD of 10 rats; ANOVA was used for multiple comparison; compared with group I, ##p<0.01; compared with group II, *p<0.05, **p<0.01.
Determination of HMG-CoA reductase, collagen, calcium and total protein in the liver.
| Group | HMG CoA/Mevalonate ratio | Collagen | Calcium | Total protein |
|---|---|---|---|---|
| (µg/mg protein) | (mg/g tissue) | (g/mg tissue) | ||
| Group I | 1.161±0.110 | 38.83±16.25 | 12.02±2.28 | 198.6±32.2 |
| Group II | 1.404±0.144## | 92.51±24.67## | 14.66±1.64# | 254.7±39.9# |
| Group III | 1.204±0.105 | 82.07±26.17** | 12.34±1.34* | 208.3±35.3 |
| Group IV | 1.158±0.150** | 76.52±41.40* | 11.87±1.64** | 200.2±51.1* |
| Group V | 1.056±0.139** | 38.95±22.94** | 11.02±1.83** | 197.3±17.6* |
| Group VI | 1.108±0.130** | 40.07±29.66** | 13.30±1.04 | 203.5±23.6* |
Values are expresses as mean±SD of 10 rats; ANOVA was used for multiple comparison; compared with group I, #p<0.05, ##p<0.01; compared with group II, *p<0.05, **p<0.01.
Fig. 2Histopathology of experimental rats. (A): No changes (Group I). (B): Multifocal severe fragmentation of elastic and collagen fibres in media with marked mineralization (Group II). (C): Moderate multifocal splitting of media with marked peripheral mineralization (Group III). (D): Moderate multifocal marked splitting of tunica media with vacuolation and mineralization (Group IV). (E): Mild diffuse thickening and fragmentation of media with mild mineralization; focal rupture of intima and media (Group V). (F): Mild multifocal fragmentation of elastic and collagen fibres in media with mineralization; focal rupture of intima & media (Group VI).